Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

FTY720 immunomodulation: optimism for improved transplant regimens.

R Ferguson1

  • 1Division of Transplantation, Ohio State University, Columbus 43210, USA. ferguson.7@osu.edu

Transplantation Proceedings
|March 26, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Wrist pain: a systematic review of prevalence and risk factors- what is the role of occupation and activity?

BMC musculoskeletal disorders·2019
Same author

Toxicity and Efficacy of Stereotactic Ablative Body Radiotherapy for Moderately Central Non-small Cell Lung Cancers Using 50 Gy in Five Fractions.

Clinical oncology (Royal College of Radiologists (Great Britain))·2019
Same author

<sup>68</sup>Ga-PSMA PET/CT vs. mpMRI for locoregional prostate cancer staging: correlation with final histopathology.

Prostate cancer and prostatic diseases·2018
Same author

Predation risk and habitat selection in the persistence of a remnant caribou population.

Oecologia·2017
Same author

Plasmacytoid dendritic cell-derived IFNα modulates Th17 differentiation during early Bordetella pertussis infection in mice.

Mucosal immunology·2015
Same author

Incidence of upper gastrointestinal haemorrhage in Maori and New Zealand European ethnic groups, 2001-2010.

Internal medicine journal·2014
Same journal

Analysis of the Cost of Maintaining Effective Donors and Nondonors of Organs and Tissues in Intensive Care Units.

Transplantation proceedings·2026
Same journal

Adolescence and Pediatric Heart Transplantation: Impact of Non-Adherence on Mortality: A Single-Center Experience.

Transplantation proceedings·2026
Same journal

Impact of Family-Based Care on the Outcome of Brain Death and Humanization in the Process of Multiple Organ Donation: Case Report.

Transplantation proceedings·2026
Same journal

Karnofsky Performance Status Is Associated with Patient and Graft Survival After Liver Retransplantation.

Transplantation proceedings·2026
Same journal

Evaluating CMV Risk Stratification, Donor Characteristics, and Post-Transplant Outcomes in Kidney Transplant Recipients: A Retrospective Eurotransplant Center Analysis.

Transplantation proceedings·2026
Same journal

Twenty-One Years of Insights From A Single-Center Living Kidney Donation Program.

Transplantation proceedings·2026
See all related articles

FTY720, a novel immunomodulator, effectively prevents organ transplant rejection. It allows reduced immunosuppressant doses, offering improved efficacy and tolerability compared to standard regimens.

Area of Science:

  • Immunology
  • Transplantation Medicine
  • Pharmacology

Background:

  • FTY720 is a sphingosine 1-phosphate receptor (S1P-R) agonist, representing a new class of immunomodulators.
  • Preclinical studies demonstrated FTY720's efficacy in preventing graft rejection across cardiac, renal, and hepatic transplantation models.
  • Phase I trials in renal transplant patients indicated a favorable safety and efficacy profile.

Purpose of the Study:

  • To determine optimal dosing for acute rejection prevention with FTY720.
  • To evaluate FTY720's efficacy and tolerability in combination with reduced and full-dose cyclosporine (CsA).
  • To assess FTY720's safety profile in combination with other immunosuppressive agents.

Main Methods:

  • Phase II clinical studies were conducted in stable renal transplant patients.

Related Experiment Videos

  • FTY720 dosing was optimized for acute rejection prevention.
  • Combination therapy with reduced/full-dose CsA and other agents like everolimus was evaluated.

    • Main Results:

    • FTY720 5 mg with reduced-dose CsA achieved efficacy comparable to mycophenolate mofetil (MMF)/CsA for acute rejection prevention.
    • A 5-mg dose of FTY720 allowed for a 50% reduction in calcineurin inhibitor dosage while maintaining rejection prophylaxis.
    • FTY720 demonstrated no overlapping toxicity with traditional immunosuppressants and was safe with CsA and everolimus.

    Conclusions:

    • FTY720, particularly at 5 mg, offers a promising alternative for immunosuppression in organ transplantation.
    • The drug enables significant reduction in calcineurin inhibitor doses, potentially improving tolerability.
    • FTY720's synergistic effects suggest a substantial improvement in the efficacy and safety of future immunosuppressive strategies.